Zeteo Tech Expands IP Portfolio of Mass Spectrometry Technology
“This latest patent adds to Zeteo Tech’s robust IP portfolio protecting our technology that can perform rapid analysis of biological aerosols, including bacteria, viruses, and toxins,” said Dr. Wayne Bryden, President and CEO of Zeteo Tech.
- “This latest patent adds to Zeteo Tech’s robust IP portfolio protecting our technology that can perform rapid analysis of biological aerosols, including bacteria, viruses, and toxins,” said Dr. Wayne Bryden, President and CEO of Zeteo Tech.
- In addition, Zeteo Tech has 12 mass spectrometry related foreign patents, (11 granted and 1 allowed).
- “BioFlyte emerged from Zeteo Tech’s impressive portfolio of proprietary mass spectrometry technology, and our ongoing strategic partnership has been critical for our growth,” said BioFlyte CEO Todd Sickles.
- “With Zeteo’s support, BioFlyte is commercializing this groundbreaking rapid threat detection technology to protect people, critical infrastructure, and more.”
To learn more about Zeteo Tech and its technology, please visit www.zeteotech.com .